Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Antiviral Activity and Safety, Tolerability, and Pharmacokinetics of BMS-650032 in Subjects Infected With Hepatitis C Virus Genotype 1

NCT00722358 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT00722358
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00722358 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Antiviral Activity and Safety, Tolerability, and Pharmacokinetics of BMS-650032 in Subjects Infected With Hepatitis C Virus Genotype 1
Lead sponsor
Bristol-Myers Squibb
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2008
Completion date
December 31, 2009
Enrollment
15 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis c